Focus Stocks
Mylan Bearish Signs
Published on Wednesday, 07 December 2011 04:03 Written by TradersHuddle Staff
New York, December 7th (TradersHuddle.com) - Shares of Mylan Inc. (NASDAQ:MYL) ended the trading session lower by $0.18 or -0.9% from its previous close. Mylan's price action formed what is considered to be a bearish engulfing candlestick chart pattern.
Mylan Inc. (NASDAQ:MYL) is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.
Mylan's current stock range is defined by calculated support defined at $17.22 and by the resistance level at $20.35, which should be used by traders planning their trades.
Traders wanting to establish a position in Mylan stock need to pay close attention at the bearish engulfing pattern, since it could mark a trend reversal to current Mylan shares price action. The Bearish engulfing pattern is a leading warning sign, therefore traders should closely monitor price action for indications of a trend reversal. Below an Engulfing Bearish Candle Illustration:

Related Articles
- NASDAQ 100's Update, In focus: NWSA, STX, MYL, CSCO, NTAP
- NASDAQ 100 Mid-day Update: Lower Top Performers: EBAY, GILD, FFIV
- NASDAQ 100 Mid-day Update: Higher Top Performers: BBBY, ROST, SBUX
- New Ratings ( ZMH, SYK, PT, CEMP, SPNC, GTIV, MYL, WPI, TRS )
- Apollo - NASDAQ 100 Worst Performer
- NASDAQ 100 Round Up - Lower: GRMN, INTU, MYL
- Research Analyst's Up/Downgrades ( ATHN, YGE, CVI, MYL, HFC, JKS, TSL, CVE, CW, NTCT )
Related Partner Headlines
- Mylan Launches Generic Version of Plavix Tablets - Benzinga
- Headline CPI in Line as Inflation Remains in Check - Benzinga
- Mylan Launches Generic Lipitor in Five European Countries - Benzinga
- Mylan Increases 2012 Guidance Range to $2.45-2.55 vs $2.30-2.50; Announces $500M Share Repurchase Program - Benzinga
- UPDATE: Mylan Launches First Generic Version of Doryx® 150 mg - Benzinga
- UPDATE: Teva Settles Nuvigil Litigation with Mylan - Benzinga
- Mylan Announces Settlement Agreement for its First-to-File Generic Version of Nuvigil - Benzinga
- Analysts Get Hooked On Watson, Actavis Drugs Deal - TheStreet.com
- Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva - Benzinga
- Watson Pharma Gets Actavis at 'Generics' Price - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Alibaba and Yahoo! Finalize Deal - TheStreet.com -
Facebook Likes Obama More Than Romney - TheStreet.com -
Lowe's: S&P Intraday Laggard - TheStreet.com -
The Dip-Buyers Aren't Biting - TheStreet.com -
Wal-Mart Stores Reaches New 52-Week High (WMT) - TheStreet.com -
Sirius XM Needs an Entrepreneur at the Helm - TheStreet.com -
Attention Gold Bulls: Oil Is Leading the Way - TheStreet.com -
Knightsbridge Tankers Stock Hits New 52-Week Low (VLCCF) - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,457.48 Trade time:11:14AM EDT Value change:▲88.10 (0.71%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,308.33 Trade time:11:14AM EDT Value change:▲13.11 (1.01%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,813.42 Trade time:11:14AM EDT Value change:▲34.63 (1.25%)In The Wires
-
SYNNEX Corporation Moves Up on Fortune 500 List for 6th Year in a Row -
Thunderbird Hosts Global Business Dialogue in Berlin -
CORRECTING and REPLACING Douglas and Sandra Bergeron Fund Endowment at Georgetown University Medical Center -
Boardwalk to Present at 2012 Master Limited Partnership Investor Conference -
ADDING and REPLACING Green Dot Announces New Exclusive Distribution and Key Contract Renewals -
QED Proof of Concept Program Opens Fifth Round With New Participants and New Special Emphasis Topic -
Pie Five Pizza Co. Brings Zen to the Menu With Sweet Thai Pie -
SGOCO Announces Delay of 2011 Year End Financial Results Due to Change of Auditor









